• $14.4M
    Market Cap
  • -67.54%
    1-Year Change
  • Biotechnology
    Industry
Annual
Quarterly
12/31/2025
12/31/2024
12/31/2023
12/31/2022
Income Statement
Total Operating Revenue
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Cost of Revenue
2.3M
-5.64%
2.5M
-43.89%
4.4M
N/A
N/A
N/A
Gross Profit
-2.3M
-5.64%
-2.5M
-43.89%
-4.4M
N/A
0
N/A
Sales and Marketing Expense
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Research and Development Expense
-5.8M
-48.50%
-11.3M
-38.38%
-18.4M
+8.27%
-17.0M
+168.03%
Depreciation and Amortization Expense
70,000
+32.08%
53,000
-20.90%
67,000
+15.52%
58,000
+70.59%
Total Operating Expenses
9.6M
-35.09%
14.7M
-42.11%
25.5M
-10.77%
28.5M
+130.72%
Operating Profit
-9.0M
-35.50%
-13.9M
-42.43%
-24.2M
-14.05%
-28.2M
+125.84%
Interest Income
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Interest Expense
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Interest Income and Expense and Net
0
N/A
0
N/A
0
N/A
0
N/A
Total Nonoperating Income and Expense
572,000
-27.96%
794,000
-35.86%
1.2M
+250.71%
353,000
N/A
Income before Taxes
-9.0M
-35.50%
-13.9M
-42.43%
-24.2M
-14.05%
-28.2M
+125.84%
Income Taxes
0
N/A
0
N/A
0
+100.00%
-534,000
N/A
Extraordinary Items
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Net Income
-9.0M
-35.50%
-13.9M
-42.43%
-24.2M
-12.39%
-27.6M
+121.56%
Net Income from Continuing Operations Applicable to Common
-9.0M
-35.50%
-13.9M
-42.43%
-24.2M
-14.05%
-28.2M
+125.84%
Basic EPS and Net Income
0.02
-53.85%
0.04
-62.14%
0.10
-14.88%
0.12
+101.67%
Diluted EPS and Net Income
0.02
-53.85%
0.04
-62.14%
0.10
-14.88%
0.12
+101.67%
Basic Weighted Average Shares
510.2M
+42.11%
359.0M
+52.79%
235.0M
+3.26%
227.6M
+9.70%
Diluted Weighted Average Shares
510.2M
+42.11%
359.0M
+52.79%
235.0M
+3.26%
227.6M
+9.70%
Balance Sheet
Cash and Cash Equivalents
7.6M
+24.59%
6.1M
-34.66%
9.3M
-31.27%
13.5M
-10.98%
Short-Term Investments
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Cash and Cash Equivalents and Short-Term Investments
7.6M
+24.59%
6.1M
-34.66%
9.3M
-31.27%
13.5M
-10.98%
Total Current Assets
13.4M
-16.30%
16.0M
-23.24%
20.9M
-49.93%
41.7M
-33.42%
Accumulated Depreciation
311,000
+11.47%
279,000
+23.45%
226,000
+36.97%
165,000
+54.21%
Property and Plant and Equipment and Net
176,000
-29.60%
250,000
-17.49%
303,000
-17.44%
367,000
+2.80%
Total Long-Term Assets
387,000
-58.12%
924,000
-26.32%
1.3M
-5.50%
1.3M
-20.30%
Total Assets
13.8M
-18.58%
17.0M
-23.42%
22.2M
-48.56%
43.1M
-33.08%
Income Taxes Payable
538,000
0.00%
538,000
N/A
N/A
N/A
N/A
N/A
Total Short-Term Debt
N/A
N/A
N/A
N/A
N/A
N/A
949,000
+171.14%
Total Current Liabilities
1.5M
-54.07%
3.2M
-33.48%
4.8M
-28.32%
6.7M
+154.68%
Total Long-Term Debt
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Total Long-Term Liabilities
0
-100.00%
209,000
-33.86%
316,000
+247.25%
91,000
-61.60%
Total Liabilities
1.5M
-56.87%
3.4M
-33.51%
5.2M
-24.65%
6.8M
+136.92%
Retained Earnings
-111.6M
+8.77%
-102.6M
+15.73%
-88.7M
+38.95%
-63.8M
+76.43%
Total Stockholders Equity
12.3M
-8.89%
13.5M
-20.36%
17.0M
-53.08%
36.2M
-41.07%
Total Shares Outstanding
575.4M
+52.57%
377.1M
+32.75%
284.1M
+22.12%
232.6M
+1.99%
Cash Flow
Cash from Operating Activities
-11.1M
-27.66%
-15.4M
-34.84%
-23.6M
+15.91%
-20.4M
+64.62%
Capital Expenditures
3,000
N/A
0
-100.00%
3,000
-95.59%
68,000
-71.55%
Cash from Investing Activities
5.4M
+134.65%
2.3M
-85.53%
15.9M
-18.71%
19.5M
+143.23%
Dividends Paid
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Cash from Financing Activities
7.2M
-27.47%
9.9M
+181.62%
3.5M
+533.66%
-808,000
-101.32%
Financials Ratio
Gross Margin
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Operating Margin
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Return on Assets
-58.45%
-18.02%
-71.30%
-4.01%
-74.28%
+44.31%
-51.47%
+45.48%
Return on Equity
-69.54%
-23.87%
-91.34%
+0.35%
-91.02%
+60.82%
-56.60%
+47.52%
Revenue Growth
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Current Ratio
9.08
+82.23%
4.98
+15.40%
4.32
-30.15%
6.18
-73.86%
Cash Ratio
5.12
+171.27%
1.89
-1.77%
1.92
-4.12%
2.00
-65.05%
Debt-to-Equity Ratio
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Debt-to-Assets Ratio
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A

Earnings & Revenue History

Debt-to-Assets

Cash Flow